Matt Shair and Jim Porter (Nuvalent)
Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene
When Matt Shair unveiled a $50 million Series A for his latest targeted therapy startup earlier this year, the Harvard professor was pleased with how …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
